News|Articles|May 28, 2026
The eCOA Iceberg: Uncovering the Hidden Costs of Software-Only Models
Author(s)Castor
When evaluating eCOA vendors, the license fee is just the tip of the iceberg. This brief examines the true Total Cost of Ownership (TCO) for eCOA in clinical trials, revealing the hidden operational, integration, and service costs that hit biotech sponsors and how natively integrated platforms prevent budget overruns.
Related Content
Trending on Applied Clinical Trials Online
1
FDA Pauses Real-Time Release of Drug Rejection Letters While Working to Formalize Policy
2
ACT Brief: Single Pivotal Trial Stakes, Configurable FSP Strategy, and G-CSF Biosimilar Portfolio Expansion
3
Tailoring Your FSP Approach: Why One Model Doesn’t Fit Every Trial
4
Bringing the Voice of Clinical Practice and Patients into Drug Development
5